Shots:
- Sanofi to acquire all outstanding shares of Kiadis for $6.34/ share, representing an equity value of $358.76M. The offer price represents a premium of 272% over the closing price on Oct 30, 2020, a premium of ~247% over the 30 trading days VWAP and a premium of ~200% over the 90 trading days VWAP
- The transaction is expected to be completed in H1’21. The addition of Kiadis’ NK cell platform and pipeline of cell-based cancer immune-therapeutics & infectious disease therapies complements Sanofi’s existing therapeutic expertise
- In July’2020, Sanofi licensed Kiadis’ pre-clinical K-NK004 program for MM. Sanofi’s infrastructure and capabilities will be leveraged to advance the development of Kiadis’ pipeline
Click here to read the full press release/ article | Ref: Sanofi | Image: Kiadis
The post Sanofi to Acquire Kiadis for ~8M first appeared on PharmaShots.
